Coherus Oncology (CHRS) Net Margin Growth (5y) (2019 - 2026)

Coherus Oncology (CHRS) Net Margin Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 19,698.00
Dec 31, 2025 5,949.00
Sep 30, 2025 5,203.00
Jun 30, 2025 329,536.00
Mar 31, 2025 -15,130.00
Dec 31, 2024 -9,123.00
Sep 30, 2024 56,453.00
Jun 30, 2024 37,900.00
Mar 31, 2024 745,908.00
Jun 30, 2022 473,363.00
Mar 31, 2022 5.15 Mn
Dec 31, 2021 892,220.00
Sep 30, 2021 -9,718.00
Jun 30, 2021 42,857.00
Mar 31, 2021 31,918.00
Dec 31, 2020 52,073.00
Sep 30, 2020 101,977.00
Jun 30, 2020 90,383.00
Mar 31, 2020 66,311.00
Dec 31, 2019 44,076.00